| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Roche Holding AG ADR | Prasinezumab (PRX002) | Parkinson's disease | Phase 3 | Ongoing | Intravenous | Neurology |
| Roche Holding AG ADR | Gantenerumab - (GRADUATE) | Early Alzheimer's disease | Phase 3 | Trial Completed | Intravenous | Neurology |
| Roche Holding AG ADR | Mytesi (crofelemer) - (HALT-D) | Cancer related diarrhea (CRD) | Phase 3 | Trial Completed | Oral | Oncology |
| Roche Holding AG ADR | Hemlibra - (HAVEN 6) | Hemophilia A | Phase 3 | Subcutaneous | Hematology | |
| Roche Holding AG ADR | Gazyva - (GALLIUM) | Follicular lymphoma | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | Tiragolumab - (SKYSCRAPER-03) | Stage III Unres. Non-Small Cell Lung Cancer | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | Tiragolumab - (SKYSCRAPER-08) (China Only) | 1L Esophageal Squamous Cell Cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Roche Holding AG ADR | Tiragolumab - (SKYSCRAPER-02) | 1L Extensive-Stage Small Cell Lung Cancer | Phase 3 | Intravenous | Oncology |